Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

If you haven’t lived underneath a rock for the past decade or so, you will have seen a lot of arguing in the media by ...

Alphabet delivered a record-breaking Q3 with over $102 billion in revenue, driven by strong growth across Google Services and ...

A mathematical proof has finally debunked the idea that we live in a simulation, according to a group of international ...

In a recent survey of law school admissions officers, 94% said the current political climate in the US played at least a ...

Virtual screening methods fall broadly into two categories: ligand- and structure-based. Ligand-based virtual screening doesn’t require a target protein structure, Instead, it leverages known active ...

Microsoft Azure has been experiencing a global outage since around 1600 UTC, or 0900 PDT on Wednesday, October 29, 2025. As Azure staggers back to its feet following an hours-long outage last night, ...

With the rise in adoption of agentic AI by companies for automation and increasing complexities of the newer versions, ...

If you're an artist doing retro-style work (or you dream of getting started) and you'd like to do more with your Linux ...